Design Therapeutics (DSGN) Investor Presentation - Slideshow

Note: Treatment assignment is blinded. Based upon data transfer of August 7th 2023 *GAA repeat length of the shorter allele 9 Phase 1 MAD Study Blinded Safety DT-216 generally well tolerated; injection site reactions observed 10 | --- | --- | |--------------------------------------------------------------------------------|-------| | | | | Blinded Adverse Events | | | | | | • No serious adverse events (AEs) and no treatment-related discontinuations | | | • All AEs were mild or moderate; none were severe | | ...